Zenotech Laboratories Ltd

532039

Overview

    • Equity Style Box

      Small Growth

    • Sector

      Healthcare

    • Industry

      Drug Manufacturers - Specialty & Generic

    • Day Range

      58.30 – 61.86

    • Year Range

      51.00 – 107.79

    • Market Cap

      3.7064 Bil

    • Volume / Avg

      25.6 k / 14.8 k

    • Price / Sales

      9.29

    • Price / Book

      3.77

    • Price / Earnings

      64.49

    • Forward Div Yield

      0.00%

    • Trailing Div Yield

      —

Summary

Fair Value Assessment
Fairly Valued
Fair ValueQ60.26UncertaintyMedium
Close Price59.33May 15, 2025
After Hours: ₹ 60.73 0.00 | 0.00%
₹ 60.73
Price Up by 1.40 | 2.36 %
Trading Information Business Description
Previous Close
59.33
Day Range
58.30 – 61.86
Year Range
51.00 – 107.79
Bid / Ask
—
Market Cap
3.7 Bil
Volume / Average
25.6 k / 14.8 k
Beta (5-Year)
–
Shares Outstanding
61.03 Mil
Primary Exchange
Bombay Stock Exchange

Business Description
Zenotech Laboratories Ltd is an India-based pharmaceutical company. It is a pharmaceutical specialty generic injectables company engaged in the area of manufacturing biotechnology products. The Company’s injectables product portfolio primarily serves niche therapy areas like oncology and anesthesiology. It also manufactures products such as granulocyte-colony stimulating factor (GCSF) and Granulocyte-macrophage colony-stimulating factor (GMCSF). The company earns a vast majority of the revenue from the sale of its contract research and manufacturing services.
Contact
Survey No. 250-252 Turkapally Village, Shamirpet Mandal, Hyderabad, TG 500 078
T +91 9032044584
zenotechlab.com opens in a new tab
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Most Recent Earnings
Mar 31, 2025
Fiscal Year End
Mar 31, 2025
Employees
208
As of Mar 31, 2024

Key Metrics

Income Statement (in Mil, except ratios)
03/31/2025
03/2025
03/2024
03/2023
03/2022
03/2021
Revenue
389.76 389.76 367.62 383.53 324.94 193.73
Revenue Growth %
6.02% 6.02% -4.15% 18.03% 67.72% -25.31%
Gross Profit
381.36 381.36 325.57 347.81 299.40 169.82
Gross Profit Margin %
97.84% 97.84% 88.56% 90.69% 92.14% 87.65%
Operating Income
72.20 72.20 61.04 94.60 64.19 -31.48
Operating Margin %
18.52% 18.52% 16.60% 24.67% 19.75% -16.25%
EBIT
106.92 106.92 101.96 142.46 110.18 2.78
EBIT Margin %
27.43% 27.43% 27.74% 37.14% 33.91% 1.43%
EBITDA
176.52 176.52 172.82 214.19 179.91 67.34
EBITDA Margin %
45.29% 45.29% 47.01% 55.85% 55.37% 34.76%
Net Income
56.13 56.13 82.99 115.85 221.76 -12.15
Net Profit Margin %
14.40% 14.40% 22.57% 30.21% 68.25% -6.27%
Basic EPS
0.92 0.92 1.36 1.90 3.63 -0.20
Diluted EPS
0.92 0.92 1.36 1.90 3.63 -0.20
Normalized EPS
— — — — — —
Total Dividends per Share
— — — — — —
Balance Sheet (in Mil, except ratios)
03/31/2025
03/2025
03/2024
03/2023
03/2022
03/2021
Total Assets
1,110.31 1,110.31 1,062.06 1,008.73 940.84 858.44
Total Liabilities
149.00 149.00 156.65 186.03 234.44 374.36
Total Debt
— — — — 60.00 206.56
Total Equity
961.31 961.31 905.42 822.70 706.40 484.08
Cash And Cash Equivalents
265.75 265.75 18.16 111.42 24.15 24.58
Working Capital
234.02 234.02 126.40 -3.42 -82.01 -76.01
Shares Outstanding (Mil)
— — — 61.03 61.03 61.03
— — — 61.03 61.03 61.03
Book Value Per Share
15.75 15.75 14.84 13.48 11.57 7.93
Total Debt To Equity
— — — — 0.08 0.43
Cash Flow Statement (in Mil, except ratios)
03/31/2025
03/2024
03/2023
03/2022
03/2021
03/2020
Cash From Operating Activities
94.88 118.23 206.64 176.67 57.41 113.79
Cash From Investing Activities
152.89 -211.55 -58.24 -18.39 -48.18 -207.93
Cash From Financing Activities
— — -61.12 -158.71 4.53 -27.01
Capital Expenditures
38.63 42.34 62.32 19.38 49.12 217.47
Free Cash Flow
85.19 120.02 138.26 137.60 -1.33 -140.48
Change in Cash
247.77 -93.32 87.28 -0.43 13.76 -121.14

Profile

There is no Key Executive Team data available.
Transaction History

Shares in Thousands
0 5 10 15 20 25 30 35 40
>
No Data Available
There is no available information for this investment.
Sep
2023
    • Buy
    • Acquisition
    • Option Exercise
    • Disposition
    • Sell
Transaction Detail
No Data Available
There is no available information for this investment.

Ownership


STOCKS
MUTUAL FUNDS
ADITYABIRLAAXISBajajBANDHANBARODABNPBOICANARADSPEDELWEISSFRANKLINTEMPLETONGROWWHDFCHELIOSHSBCICICIIIFLINVESCOITIJMKOTAKLICMahindraManulifeMIRAEMOTILALNAVINipponNJOldBridgePGIMPPFASQUANTQUANTUMSAMCOSBISHRIRAMSUNDARAMTATATAURUSTrustUNIONUTIWhiteOakZERODHA
INSURANCE FUNDS
ABSLAEGONAGEASFEDERALAVIVABAJAJALLIANZBHARTIAXACANARAHSBCORIENTBANKEDELWEISSTOKIOEXIDEFUTUREGENERALIHDFCICICIPRUDENTIALINDIAFIRSTKOTAKMAHINDRALICMAXLIFEPNBMETLIFEPRAMERICARELIANCENIPPONSAHARASBISHRIRAMSTARUNIONDAI-ICHITATAAIA

About Us

Connect With Us

© Copyright 2025 Morningstar, Inc. All rights reserved.
Terms of Use    Privacy Policy
© Copyright 2025 Morningstar, Inc. All rights reserved. Please read our Terms of Use above. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
As of December 1st, 2023, the ESG-related information, methodologies, tools, ratings, data and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted, and Morningstar/Sustainalytics accepts no responsibility or liability whatsoever for the actions of third parties in this respect.
Company: Morningstar India Private Limited; Regd. Office: 9th floor, Platinum Technopark, Plot No. 17/18, Sector 30A, Vashi, Navi Mumbai – 400705, Maharashtra, India; CIN: U72300MH2004PTC245103; Telephone No.: +91-22-61217100; Fax No.: +91-22-61217200; Contact: Morningstar India Help Desk (e-mail: helpdesk.in@morningstar.com) in case of queries or grievances.
Top